The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Advanced Therapy Based on Gene Market Research Report 2024
Synopsis
Advanced Therapy Based on Gene is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.
Global Advanced Therapy Based on Gene market is projected to reach US$ 34850 million in 2029, increasing from US$ 9063 million in 2022, with the CAGR of 20.2% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Advanced Therapy Based on Gene market research.
The advanced therapy based on gene market is driven by the potential to revolutionize healthcare by offering personalized and targeted treatments for genetic disorders and other diseases. Advanced therapy based on gene includes gene therapy, cell therapy, and gene editing techniques, which aim to modify or replace faulty genes to treat or cure diseases at the genetic level. The rise in the understanding of genetic mechanisms and advancements in biotechnology and genetic engineering contribute to market growth as these therapies hold promise for previously untreatable conditions. Moreover, increasing investment in research and clinical trials and the support from regulatory agencies for accelerated approval further boost the development and commercialization of advanced gene therapies. However, the market also faces challenges, including the complexity of manufacturing and delivering gene-based therapies, safety concerns related to viral vectors and off-target effects in gene editing, and high treatment costs. Additionally, addressing regulatory requirements and ensuring accessibility and affordability of advanced gene therapies can pose obstacles for broader adoption. To succeed, companies must focus on research and development to advance the safety and efficacy of gene-based therapies, collaborate with healthcare stakeholders to build robust infrastructure, and address the challenges to fully realize the transformative potential of advanced therapy based on gene in modern medicine.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Advanced Therapy Based on Gene market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
Segment by Type
Viral
Non-viral
Segment by Application
Neurological Diseases
Cancer
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Advanced Therapy Based on Gene report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Advanced Therapy Based on Gene is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.
Global Advanced Therapy Based on Gene market is projected to reach US$ 34850 million in 2029, increasing from US$ 9063 million in 2022, with the CAGR of 20.2% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Advanced Therapy Based on Gene market research.
The advanced therapy based on gene market is driven by the potential to revolutionize healthcare by offering personalized and targeted treatments for genetic disorders and other diseases. Advanced therapy based on gene includes gene therapy, cell therapy, and gene editing techniques, which aim to modify or replace faulty genes to treat or cure diseases at the genetic level. The rise in the understanding of genetic mechanisms and advancements in biotechnology and genetic engineering contribute to market growth as these therapies hold promise for previously untreatable conditions. Moreover, increasing investment in research and clinical trials and the support from regulatory agencies for accelerated approval further boost the development and commercialization of advanced gene therapies. However, the market also faces challenges, including the complexity of manufacturing and delivering gene-based therapies, safety concerns related to viral vectors and off-target effects in gene editing, and high treatment costs. Additionally, addressing regulatory requirements and ensuring accessibility and affordability of advanced gene therapies can pose obstacles for broader adoption. To succeed, companies must focus on research and development to advance the safety and efficacy of gene-based therapies, collaborate with healthcare stakeholders to build robust infrastructure, and address the challenges to fully realize the transformative potential of advanced therapy based on gene in modern medicine.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Advanced Therapy Based on Gene market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
Segment by Type
Viral
Non-viral
Segment by Application
Neurological Diseases
Cancer
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Advanced Therapy Based on Gene report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Advanced Therapy Based on Gene Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Viral
1.2.3 Non-viral
1.3 Market by Application
1.3.1 Global Advanced Therapy Based on Gene Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Neurological Diseases
1.3.3 Cancer
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Advanced Therapy Based on Gene Market Perspective (2018-2029)
2.2 Advanced Therapy Based on Gene Growth Trends by Region
2.2.1 Global Advanced Therapy Based on Gene Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Advanced Therapy Based on Gene Historic Market Size by Region (2018-2023)
2.2.3 Advanced Therapy Based on Gene Forecasted Market Size by Region (2024-2029)
2.3 Advanced Therapy Based on Gene Market Dynamics
2.3.1 Advanced Therapy Based on Gene Industry Trends
2.3.2 Advanced Therapy Based on Gene Market Drivers
2.3.3 Advanced Therapy Based on Gene Market Challenges
2.3.4 Advanced Therapy Based on Gene Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Advanced Therapy Based on Gene Players by Revenue
3.1.1 Global Top Advanced Therapy Based on Gene Players by Revenue (2018-2023)
3.1.2 Global Advanced Therapy Based on Gene Revenue Market Share by Players (2018-2023)
3.2 Global Advanced Therapy Based on Gene Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Advanced Therapy Based on Gene Revenue
3.4 Global Advanced Therapy Based on Gene Market Concentration Ratio
3.4.1 Global Advanced Therapy Based on Gene Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Advanced Therapy Based on Gene Revenue in 2022
3.5 Advanced Therapy Based on Gene Key Players Head office and Area Served
3.6 Key Players Advanced Therapy Based on Gene Product Solution and Service
3.7 Date of Enter into Advanced Therapy Based on Gene Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Advanced Therapy Based on Gene Breakdown Data by Type
4.1 Global Advanced Therapy Based on Gene Historic Market Size by Type (2018-2023)
4.2 Global Advanced Therapy Based on Gene Forecasted Market Size by Type (2024-2029)
5 Advanced Therapy Based on Gene Breakdown Data by Application
5.1 Global Advanced Therapy Based on Gene Historic Market Size by Application (2018-2023)
5.2 Global Advanced Therapy Based on Gene Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Advanced Therapy Based on Gene Market Size (2018-2029)
6.2 North America Advanced Therapy Based on Gene Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Advanced Therapy Based on Gene Market Size by Country (2018-2023)
6.4 North America Advanced Therapy Based on Gene Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Advanced Therapy Based on Gene Market Size (2018-2029)
7.2 Europe Advanced Therapy Based on Gene Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Advanced Therapy Based on Gene Market Size by Country (2018-2023)
7.4 Europe Advanced Therapy Based on Gene Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Advanced Therapy Based on Gene Market Size (2018-2029)
8.2 Asia-Pacific Advanced Therapy Based on Gene Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Advanced Therapy Based on Gene Market Size by Region (2018-2023)
8.4 Asia-Pacific Advanced Therapy Based on Gene Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Advanced Therapy Based on Gene Market Size (2018-2029)
9.2 Latin America Advanced Therapy Based on Gene Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Advanced Therapy Based on Gene Market Size by Country (2018-2023)
9.4 Latin America Advanced Therapy Based on Gene Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Advanced Therapy Based on Gene Market Size (2018-2029)
10.2 Middle East & Africa Advanced Therapy Based on Gene Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Advanced Therapy Based on Gene Market Size by Country (2018-2023)
10.4 Middle East & Africa Advanced Therapy Based on Gene Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Detail
11.1.2 Biogen Business Overview
11.1.3 Biogen Advanced Therapy Based on Gene Introduction
11.1.4 Biogen Revenue in Advanced Therapy Based on Gene Business (2018-2023)
11.1.5 Biogen Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Advanced Therapy Based on Gene Introduction
11.2.4 Novartis Revenue in Advanced Therapy Based on Gene Business (2018-2023)
11.2.5 Novartis Recent Development
11.3 Gilead Sciences
11.3.1 Gilead Sciences Company Detail
11.3.2 Gilead Sciences Business Overview
11.3.3 Gilead Sciences Advanced Therapy Based on Gene Introduction
11.3.4 Gilead Sciences Revenue in Advanced Therapy Based on Gene Business (2018-2023)
11.3.5 Gilead Sciences Recent Development
11.4 Sarepta Therapeutics
11.4.1 Sarepta Therapeutics Company Detail
11.4.2 Sarepta Therapeutics Business Overview
11.4.3 Sarepta Therapeutics Advanced Therapy Based on Gene Introduction
11.4.4 Sarepta Therapeutics Revenue in Advanced Therapy Based on Gene Business (2018-2023)
11.4.5 Sarepta Therapeutics Recent Development
11.5 Alnylam Pharmaceuticals
11.5.1 Alnylam Pharmaceuticals Company Detail
11.5.2 Alnylam Pharmaceuticals Business Overview
11.5.3 Alnylam Pharmaceuticals Advanced Therapy Based on Gene Introduction
11.5.4 Alnylam Pharmaceuticals Revenue in Advanced Therapy Based on Gene Business (2018-2023)
11.5.5 Alnylam Pharmaceuticals Recent Development
11.6 Amgen
11.6.1 Amgen Company Detail
11.6.2 Amgen Business Overview
11.6.3 Amgen Advanced Therapy Based on Gene Introduction
11.6.4 Amgen Revenue in Advanced Therapy Based on Gene Business (2018-2023)
11.6.5 Amgen Recent Development
11.7 Spark Therapeutics
11.7.1 Spark Therapeutics Company Detail
11.7.2 Spark Therapeutics Business Overview
11.7.3 Spark Therapeutics Advanced Therapy Based on Gene Introduction
11.7.4 Spark Therapeutics Revenue in Advanced Therapy Based on Gene Business (2018-2023)
11.7.5 Spark Therapeutics Recent Development
11.8 Akcea Therapeutics
11.8.1 Akcea Therapeutics Company Detail
11.8.2 Akcea Therapeutics Business Overview
11.8.3 Akcea Therapeutics Advanced Therapy Based on Gene Introduction
11.8.4 Akcea Therapeutics Revenue in Advanced Therapy Based on Gene Business (2018-2023)
11.8.5 Akcea Therapeutics Recent Development
11.9 Sunway Biotech
11.9.1 Sunway Biotech Company Detail
11.9.2 Sunway Biotech Business Overview
11.9.3 Sunway Biotech Advanced Therapy Based on Gene Introduction
11.9.4 Sunway Biotech Revenue in Advanced Therapy Based on Gene Business (2018-2023)
11.9.5 Sunway Biotech Recent Development
11.10 SIBIONO
11.10.1 SIBIONO Company Detail
11.10.2 SIBIONO Business Overview
11.10.3 SIBIONO Advanced Therapy Based on Gene Introduction
11.10.4 SIBIONO Revenue in Advanced Therapy Based on Gene Business (2018-2023)
11.10.5 SIBIONO Recent Development
11.11 AnGes
11.11.1 AnGes Company Detail
11.11.2 AnGes Business Overview
11.11.3 AnGes Advanced Therapy Based on Gene Introduction
11.11.4 AnGes Revenue in Advanced Therapy Based on Gene Business (2018-2023)
11.11.5 AnGes Recent Development
11.12 Orchard Therapeutics
11.12.1 Orchard Therapeutics Company Detail
11.12.2 Orchard Therapeutics Business Overview
11.12.3 Orchard Therapeutics Advanced Therapy Based on Gene Introduction
11.12.4 Orchard Therapeutics Revenue in Advanced Therapy Based on Gene Business (2018-2023)
11.12.5 Orchard Therapeutics Recent Development
11.13 Human Stem Cells Institute
11.13.1 Human Stem Cells Institute Company Detail
11.13.2 Human Stem Cells Institute Business Overview
11.13.3 Human Stem Cells Institute Advanced Therapy Based on Gene Introduction
11.13.4 Human Stem Cells Institute Revenue in Advanced Therapy Based on Gene Business (2018-2023)
11.13.5 Human Stem Cells Institute Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
